VX-787 Pimodivir

具體成交價以合同協(xié)議為準

公司名稱 MedChemExpress LLC
品牌 MedChemExpress (MCE)
型號 VX-787
產(chǎn)地
廠商性質 生產(chǎn)廠家
更新時間 2019/6/27 9:09:58
訪問次數(shù) 609

產(chǎn)品標簽

VX-787 pimodivir

在線交流發(fā)送詢價查看電話同類產(chǎn)品

聯(lián)系我們時請說明是化工儀器網(wǎng)上看到的信息,，謝謝!

索取相關資料

公司介紹 主營產(chǎn)品

MedChemExpress (MCE) 專注于為科學家提供高品質的生物活性小分子化合物，化合物庫及各類試劑盒,，總部位于美國新澤西,。
•   MedChemExpress (MCE) 產(chǎn)品作用于 20 多個熱門信號通路及研究領域的300多個細分靶點，擁有 10000 特異性抑制劑,、激動劑,，以及 50 活性化合物篩選庫；
•   我們堅持對所有產(chǎn)品進行嚴格質檢,，確保產(chǎn)品的高品質和高純度,；
•   MedChemExpress (MCE) 產(chǎn)品已被數(shù)萬名科學家信賴，并被大量top文獻和*引用,；
•   我們擁有專業(yè)的技術團隊追蹤前沿科研進展,，不斷豐富各個靶點的特異性產(chǎn)品，堅持做 “您身邊的抑制劑大師”,；
•   MedChemExpress (MCE) 與眾多藥企和科研機構保持深度合作,；
•   大量產(chǎn)品有中國庫存，工作日 16:00 前訂單確保當日發(fā)貨,，次日送達,。
MCE 中國站：www.MedChemExpress.cn

Hotline: 400-820-3792
Tel: 021-58955995
Email: [email protected]
Tech Support: 021-58950656

MedChemExpress - Inhibitors Agonists

MedChemExpress - Screening Libraries

MedChemExpress - Top Publications Citing Use of MCE

展開

抑制劑,，調節(jié)劑，API,，天然產(chǎn)物,，各種類型化合物庫

詳細信息 在線詢價

供貨周期	現(xiàn)貨	規(guī)格	10 mM * 1 mL；2 mg,；5 mg,；10 mg；25 mg,；50 mg
貨號	HY-12353A	應用領域	生物產(chǎn)業(yè)

Pimodivir

產(chǎn)品活性：Pimodivir (VX-787) 是一種可口服的甲型流感病毒聚合酶抑制劑,，通過抑制PB2亞基起作用。

研究領域：Anti-infection

作用靶點：Influenza Virus

In Vitro: Pimodivir rescues macrophages from virus-mediated death at non-cytotoxic concentrations 24 hpi. The EC₅₀ value for Pimodivir are 8 and 12 nM for A(H1N1) and A(H3N2) strains, respectively, whereas the CC₅₀ values are >1 μM, giving selectivity indexes (SI) > 125 and > 83 for A(H1N1) and A(H3N2) strains, respectively. Pimodivir significantly attenuates the transcription of viral M1 RNA in macrophages, which are infected with A(H1N1) or A(H3N2) strains for 8 h. Pimodivir inhibits the transcription of viral but not cellular genes. Pimodivir allows some activation of IAV-mediated expression of several cellular genes, which are involved in tryptophan and nucleotide metabolism. Pimodivir possesses excellent anti-IAV but not immuno/metabolo-modulating effect. Pimodivir (VX-787) is very potent against influenza A strains, including pandemic 2009 H1N1 and avian H5N1. Pimodivir (VX-787) shows potent activity against all influenza A virus strains tested, with an EC₅₀ range of 0.13 to 3.2 nM. Pimodivir-selected PB2 variant viruses maintain susceptibility to neuraminidase inhibitors in vitro.

In Vivo: Pimodivir (2, 6, and 20 mg/kg/day, p.o.) and oseltamivir (20 mg/kg/day) completely prevent death in the H1N1pdm virus infection in mice. Pimodivir (20 mg/kg/day) is more effective than oseltamivir (20 mg/kg/day) in improving body weight and reducing the severity of lung infection. Moreover, Pimodivir (VX-787) shows * survival in a +48 h delay to treatment mouse influenza model at 10, 3 and 1 mpk (BID × 10 days) whereas the SOC, oseltamivir, provide no survival benefit in this model at 10 mpk. Pimodivir (VX-787; 1, 3, or 10 mg/kg, bid) provided complete survival, with a dose-dependent reduction in BW loss of the mice.